Redefining the economics of upstream mAb and viral vector bioprocessing: how process intensification boosts productivity

Watch the video or view the poster to learn about:how to enable scalable perfusion production processes for lentivirus;how to achieve intensified AAV production by enhancing HEK293 cell density at transfection and specific productivity resulting in >8.9x total full capsid AAV titer yield;why process robustness and reproducibility are key for high productivity and cost-effective viral vector manufacturing at scale;how to reduce cost per dose with a perfusion process, increasing the virus productivity using 10x less bioreactor volume.Rachel has more than 20 years of experience in the field of scalable biologics and gene therapy manufacturing of therapeutic products, viral vectors and proteins for gene therapy and biologics. She completed her PhD in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology, Israel. Rachel joined Repligen in 2021 as a subject matter expert leading the vector business unit involving with setting the strategy around this fast-growing area including providing technical assistance to help customers achieve their technical and operational objectives in their manufacturing of virus-based therapeutics with a focus on gene therapy processes including upstream, downstream, analytics, and scalability.